Henry Ford Health research teams are launching a series of clinical studies in partnership with Illumina Inc., a global leader in DNA sequencing and array-based technologies, to assess the impact of comprehensive genomic testing in various disease areas.
The partnership could yield data to support the use of whole-genome sequencing in treating and managing cardiovascular disease, the leading cause of death in the US.